Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer

• DOI: 10.1126/scitranslmed.aao5931
• Publication Date: 2018-04-11T18:10:50Z
• Authors: Janos L. Tanyi; Sara Bobisse; Eran Ophir; Sandra Tuyaerts; Annalisa Roberti; Raphael Genolet; Petra Baumgartner; Brian J. Stevenson; Christian Iseli; Denarda Dangaj; Brian Czerniecki; Aikaterini Semili...; Julien Racle; Alexandra Michel; Ioannis Xenarios; Cheryl Chiang; Dimitri S. Monos; Drew A. Torigian; Harvey L. Nisenbaum; Olivier Michielin; Carl H. June; Bruce L. Levine; Daniel J. Powell; David Gfeller; Rosemarie Mick; Urania Dafni; Vincent Zoete; Alexandre Harari; George Coukos; Lana E. Kandalaft
• Keywords: Ovarian Neoplasms; Dendritic Cells; Cancer Vaccines; 3. Good health; Bevacizumab; 03 medical and health sciences; 0302 clinical medicine; Antigens, Neoplasm; Mutation; Humans; Female; Immunotherapy; Cyclophosphamide; T-Lymphocytes, Cytotoxic

Personalized cancer vaccines induce antitumor T cells that correlate with clinical benefit in patients with ovarian cancer.